Home LiteratureArticle Details
PMID: 18171295 Published · ppublish English Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

The Journal of infectious diseases ·Vol. 197 ·No. 1 ·2008-01-01 ·Pages 126-33

Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG

Abstract

Although untreated human immunodeficiency virus (HIV)-infected patients maintaining undetectable plasma HIV RNA levels (elite controllers) have high HIV-specific immune responses, it is unclear whether they experience abnormal levels of T cell activation, potentially contributing to immunodeficiency. We compared percentages of activated (CD38(+)HLA-DR(+)) T cells between 30 elite controllers, 47 HIV-uninfected individuals, 187 HIV-infected individuals with undetectable viremia receiving antiretroviral therapy (antiretroviral therapy suppressed), and 66 untreated HIV-infected individuals with detectable viremia. Because mucosal translocation of bacterial products may contribute to T cell activation in HIV infection, we also measured plasma lipopolysaccharide (LPS) levels. Although the median CD4(+) cell count in controllers was 727 cells/mm(3), 3 (10%) had CD4(+) cell counts <350 cells/mm(3) and 2 (7%) had acquired immunodeficiency syndrome. Controllers had higher CD4(+) and CD8(+) cell activation levels (P < .001 for both) than HIV-negative subjects and higher CD8(+) cell activation levels than the antiretroviral therapy suppressed (P = .048). In controllers, higher CD4(+) and CD8(+) T cell activation was associated with lower CD4(+) cell counts (P = .009 and P = .047). Controllers had higher LPS levels than HIV-negative subjects (P < .001), and in controllers higher LPS level was associated with higher CD8(+) T cell activation (P = .039). HIV controllers have abnormally high T cell activation levels, which may contribute to progressive CD4(+) T cell loss even without measurable viremia.

MeSH Terms
Adult CD4 Lymphocyte Count Cohort Studies Female HIV Infections/immunology HIV Seropositivity/immunology HIV-1/immunology Humans Lymphocyte Activation Male Middle Aged RNA, Viral/blood T-Lymphocytes/immunology,virology Viremia/immunology
Chemicals
RNA, Viral
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Hunt Peter W
Positive Health Program, San Francisco General Hospital, Bldg. 80, Ward 84, 995 Potrero Ave., San Francisco, CA 94110, USA. phunt@php.ucsf.edu
Brenchley Jason
Sinclair Elizabeth
McCune Joseph M
Roland Michelle
Page-Shafer Kimberly
Hsue Priscilla
Emu Brinda
Krone Melissa
Lampiris Harry
Douek Daniel
Martin Jeffrey N
Deeks Steven G
References (47)
47 references, click to expand
  1. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.
    J Exp Med. 2004 Sep 20;200(6):749-59 PMID: 15365096
  2. Natural killer cell function is well preserved in asymptomatic human immunodeficiency virus type 2 (HIV-2) infection but similar to that of HIV-1 infection when CD4 T-cell counts fall.
    J Virol. 2006 Mar;80(5):2529-38 PMID: 16474159
  3. AIDS enteropathy: occult enteric infections and duodenal mucosal alterations in chronic diarrhea.
    Ann Intern Med. 1991 Mar 1;114(5):366-72 PMID: 1992878
  4. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men.
    J Infect Dis. 1994 Jun;169(6):1244-9 PMID: 8195600
  5. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection.
    Nat Med. 1996 Apr;2(4):405-11 PMID: 8597949
  6. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
    Ann Intern Med. 1997 Jun 15;126(12):946-54 PMID: 9182471
  7. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Oct 1;16(2):83-92 PMID: 9358102
  8. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.
    Science. 1997 Nov 21;278(5342):1447-50 PMID: 9367954
  9. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):332-40 PMID: 9704938
  10. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection.
    AIDS. 1998 Oct 1;12(14):1833-44 PMID: 9792384
  11. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1.
    N Engl J Med. 1999 Jan 21;340(3):236-7 PMID: 9917232
  12. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.
    J Infect Dis. 1999 Apr;179(4):859-70 PMID: 10068581
  13. HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women.
    AIDS. 1999 Oct 1;13(14):1990-1 PMID: 10513667
  14. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.
    Nature. 2004 Dec 9;432(7018):769-75 PMID: 15592417
  15. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients.
    J Immunol. 2005 Mar 15;174(6):3143-7 PMID: 15749840
  16. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors.
    Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9860-5 PMID: 15980151
  17. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.
    Clin Infect Dis. 2005 Oct 1;41(7):1053-6 PMID: 16142675
  18. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells.
    Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13974-9 PMID: 16174727
  19. The independent effect of drug resistance on T cell activation in HIV infection.
    AIDS. 2006 Mar 21;20(5):691-9 PMID: 16514299
  20. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
    J Infect Dis. 2006 Jul 1;194(1):29-37 PMID: 16741879
  21. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.
    Blood. 2006 Jun 15;107(12):4781-9 PMID: 16467198
  22. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.
    J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34 PMID: 16810109
  23. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.
    JAMA. 2006 Sep 27;296(12):1498-506 PMID: 17003398
  24. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS.
    Blood. 2006 Dec 1;108(12):3808-17 PMID: 16902147
  25. Microbial translocation is a cause of systemic immune activation in chronic HIV infection.
    Nat Med. 2006 Dec;12(12):1365-71 PMID: 17115046
  26. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors.
    J Virol. 2007 Mar;81(5):2508-18 PMID: 17151109
  27. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection.
    JAMA. 2007 Jun 6;297(21):2349-50 PMID: 17551128
  28. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.
    J Infect Dis. 2003 May 15;187(10):1534-43 PMID: 12721933
  29. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group.
    AIDS. 2000 Jan 28;14(2):123-31 PMID: 10708282
  30. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.
    Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14 PMID: 10694578
  31. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.
    J Virol. 2001 Aug;75(15):6953-61 PMID: 11435575
  32. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients.
    Blood. 2001 Aug 15;98(4):906-12 PMID: 11493432
  33. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection.
    J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):346-55 PMID: 11917238
  34. Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia.
    AIDS. 2002 Mar 29;16(5):791-3 PMID: 11964537
  35. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load.
    J Immunol. 2002 Sep 15;169(6):3400-6 PMID: 12218162
  36. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions.
    Nat Immunol. 2003 Jan;4(1):49-54 PMID: 12469117
  37. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.
    Immunity. 2003 Mar;18(3):441-52 PMID: 12648460
  38. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function.
    J Infect Dis. 2003 Apr 1;187(7):1038-45 PMID: 12660917
  39. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.
    J Virol. 2003 Nov;77(21):11708-17 PMID: 14557656
  40. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells.
    J Virol. 2004 May;78(10):5223-32 PMID: 15113904
  41. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.
    Blood. 2004 Aug 15;104(4):942-7 PMID: 15117761
  42. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract.
    J Exp Med. 2004 Sep 20;200(6):761-70 PMID: 15365095
  43. Seroconversion following nonoccupational postexposure prophylaxis against HIV.
    Clin Infect Dis. 2005 Nov 15;41(10):1507-13 PMID: 16231265
  44. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment.
    J Virol. 2005 Nov;79(22):14169-78 PMID: 16254352
  45. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters.
    AIDS. 2005 Nov 18;19(17):2001-7 PMID: 16260907
  46. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis.
    Nat Med. 2005 Dec;11(12):1290-2 PMID: 16288280
  47. Gastrointestinal function and structure in HIV-positive patients.
    CMAJ. 1990 Oct 1;143(7):641-6 PMID: 2207920
Article Info
Journal
The Journal of infectious diseases
Abbr.
J Infect Dis
ISSN
0022-1899
Published
2008-01-01
Pages
126-33
Language
English
Region
United States
NLM ID
0413675
PMCID
PMC3466592
Subset
IM
Grants
NIMH NIH HHS · P30 MH062246 · United States
NINDS NIH HHS · NS 37660 · United States
NINDS NIH HHS · R01 NS037660 · United States
NIAID NIH HHS · K23 AI65244 · United States
NIAID NIH HHS · R01 AI052745 · United States
NIAID NIH HHS · K23 AI065244 · United States
NIH HHS · DP1 OD000329 · United States
NIMH NIH HHS · P30 MH59037 · United States
NCRR NIH HHS · 5-MO1-RR00083-37 · United States
NIAID NIH HHS · P30 AI027763 · United States
NIH HHS · DPI OD00329 · United States
NIAID NIH HHS · R37 AI040312 · United States
NCRR NIH HHS · M01 RR000083 · United States
NIAID NIH HHS · R01 AI 52745 · United States
NIMH NIH HHS · P30 MH62246 · United States
NIAID NIH HHS · P30 AI27763 · United States
NIAID NIH HHS · R37 AI40312 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com